Protocol Ledger

NCT07803965 · Phase II · RECRUITING

Study of SGC001 Injection for Predicted Severe Acute Pancreatitis to Assess Safety, Tolerability and Preliminary Efficacy

Interventional Phase II clinical trial protocol NCT07803965 sponsored by Beijing Sungen Biomedical Technology Co in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-09-30 Enrollment: 129 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07803965
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)129 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07803965
Protocol FieldVerified Registry Value
NCT IdentifierNCT07803965
Consolidated Lead SponsorBeijing Sungen Biomedical Technology Co
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment129 participants (ESTIMATED)
Registered Start Date2026-09-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI